Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia
This study is ongoing, but not recruiting participants.
First Received: June 6, 2001   Last Updated: June 23, 2005   History of Changes
Sponsored by: Northwestern Memorial Hospital
Information provided by: Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier: NCT00017654
  Purpose

OBJECTIVES:

I. Determine the effect of supplementation with donor T-cell depleted, CD34+ peripheral blood stem cells on durable engraftment and incidence of graft-versus-host disease in patients with aplastic anemia undergoing allogeneic bone marrow transplantation.


Condition Intervention
Graft Versus Host Disease
Aplastic Anemia
Drug: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: cyclosporine
Drug: methylprednisolone
Procedure: Allogeneic Bone Marrow Transplantation

Study Type: Interventional
Study Design: Treatment

Resource links provided by NLM:


Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment: 3
Study Start Date: April 2001
Detailed Description:

PROTOCOL OUTLINE: Bone marrow and peripheral blood stem cells (PBSC) are harvested from a HLA identical or 1 antigen mismatched related donor. PBSC are selected for CD34+ cells and T cells are depleted. Patients receive cyclophosphamide IV over 2 hours on days -6 to -3 and anti-thymocyte globulin IV with methylprednisolone IV over 10-12 hours on days -5 to -3. T-cell depleted PBSC and bone marrow are infused on day 0. Patients receive cyclosporine IV over 12-24 hours on days -1 to 120 followed by a taper and methylprednisolone IV on days 7-64 for graft-versus-host disease prophylaxis.

Patients are followed every 30 days for 1 year, every 60 days for 2 years, and then as needed for a minimum of 3 years.

  Eligibility

Ages Eligible for Study:   15 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

  • Diagnosis of life-threatening or transfusion-dependent marrow or immune-mediated failure involving one or more hematopoietic cell lines evidenced by one or more of the following: Granulocyte count less than 500/mm3 Platelet count less than 20,000/mm3 Absolute reticulocyte count less than 60,000/mm3
  • Immune-mediated anemia and/or thrombocytopenia must have failed corticosteroids and cyclosporine
  • Paroxysmal nocturnal hemoglobinuria with progressive marrow failure allowed
  • Either congenital or acquired severe granulocytopenia with a history of life threatening infections No diagnosis of Fanconi's anemia
  • HLA identical or 1 antigen mismatched related donor meeting the following criteria: No prior or concurrent malignancy except localized basal cell or squamous cell skin cancer (malignancies judged to be cured by local surgery, such as head and neck cancer or stage I breast cancer, considered on an individual basis) Negative pregnancy test

--Patient Characteristics--

  • Hepatic: Hepatitis B surface antigen negative Bilirubin no greater than 2.0 mg/dL Transaminases no greater than 2 times upper limit of normal (in the absence of Gilbert's disease)
  • Renal: Creatinine no greater than 2.0 mg/dL
  • Cardiovascular: No history of coronary artery disease LVEF at least 40% by MUGA
  • Pulmonary: FEV1 at least 50% predicted FVC at least 50% predicted DLCO at least 50% predicted
  • Other: No uncontrolled diabetes mellitus No other illness that would preclude aggressive chemotherapy No prior or concurrent malignancy except localized basal cell or squamous cell skin cancer (malignancies judged to be cured by local surgery, such as head and neck cancer or stage I breast cancer, considered on an individual basis) No psychiatric illness or mental deficiency that would preclude study Not pregnant or nursing Fertile patients must use effective contraception HIV negative
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00017654

Locations
United States, Illinois
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern Memorial Hospital
Investigators
Study Chair: Richard K. Burt Northwestern Memorial Hospital
  More Information

No publications provided

Study ID Numbers: 199/14983, NU-96AA1T, NU-96H
Study First Received: June 6, 2001
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00017654     History of Changes
Health Authority: Unspecified

Keywords provided by Office of Rare Diseases (ORD):
aplastic anemia
disease-related problem/condition
graft versus host disease
hematologic disorders
rare disease

Study placed in the following topic categories:
Anti-Inflammatory Agents
Cyclosporine
Immunologic Factors
Methylprednisolone
Aplastic Anemia
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Prednisolone acetate
Cyclophosphamide
Hormones
Neuroprotective Agents
Cyclosporins
Graft Versus Host Disease
Antifungal Agents
Anemia, Aplastic
Alkylating Agents
Methylprednisolone Hemisuccinate
Antineoplastic Agents, Hormonal
Hematologic Diseases
Rare Diseases
Anemia
Methylprednisolone acetate
Glucocorticoids
Immunosuppressive Agents
Homologous Wasting Disease
Antilymphocyte Serum
Prednisolone
Graft vs Host Disease
Peripheral Nervous System Agents

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Anti-Infective Agents
Cyclosporine
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Methylprednisolone
Antineoplastic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Prednisolone acetate
Cyclophosphamide
Hormones
Neuroprotective Agents
Cyclosporins
Antifungal Agents
Therapeutic Uses
Anemia, Aplastic
Dermatologic Agents
Alkylating Agents
Methylprednisolone Hemisuccinate
Antineoplastic Agents, Hormonal
Immune System Diseases
Hematologic Diseases
Gastrointestinal Agents
Anemia
Methylprednisolone acetate
Enzyme Inhibitors
Glucocorticoids
Protective Agents

ClinicalTrials.gov processed this record on July 02, 2009